RUNX2 and ocular melanoma: The RUNX2 activator, distal-less homeobox 5 (DLX5) was also found to have increased 8 fold (Fig. 1c) in OM + SW (8.398 ± 0.993) when compared to the OM control (1.013 ± 0.180).